× Close Menu
The last several years have let to numerous new treatments for Lung Cancer. At least 10 new drugs and indications have been approved in the last 3 years, which dwarfs the improvements we had over the previous two decades. Nevertheless, there remains a lot to be done.
Despite the advent of immunotherapy, these drugs either don’t work for a significant number of patients, or only work for a while. There are at least 3-4 novel agents that are in trial now that have significant activity, but the trials need to be completed in order to get them to patients.
Virginia Cancer Specialists (VCS) and the VCS Research Institute is at the forefront with many of these agents in clinical trials.
They are offered to patients who may benefit from them, or just patients looking for more cutting edge therapy. While not every patient may benefit from them, a large percentage of our lung cancer patients enroll on trials in attempt to benefit themselves as well as others.
For more information on Lung Cancer See Here:
Array (  => Array ( [acf_fc_layout] => physician_information [title] => [display_all] => 1 [stretch_to_fit] => [hide_search] => 1 [add_url_to_image] => 1 [manual_sorting] => [physicians] => Array (  => WP_Post Object ( [ID] => 547 [post_author] => 2 [post_date] => 2017-09-08 15:33:13 [post_date_gmt] => 2017-09-08 15:33:13 [post_content] => Dr. Alex Spira earned his medical degree from the New York University School of Medicine. He then went on to complete his internship and residency at the Hospital of the University of Pennsylvania, and his medical oncology fellowship at Johns Hopkins Hospital. During his training, Dr. Spira was granted many awards and honors, and he completed several specialized fellowship programs. Among these honors were the National Institutes of Health Medical Scientist Training Program Fellowship (1990-1997), Merck Corporation Scholarship (1995-1995), Pediatric AIDS Foundation Fellowship (1993- 1995) and Harvard University Scholarship (1987-1990). Dr. Spira has also received his PhD from the New York School of Arts and Sciences. As Director of the Virginia Cancer Specialists (VCS) Research Institute and the Phase I Trial Program, Dr. Spira is actively involved in advancing medicine and offering targeted treatment options for patients. Although his research interests are numerous, Dr. Spira particularly enjoys studying immunotherapy, personalized medicine, GI, thoracic and lung cancer and sarcomas. Dr. Spira is also Co-Chair of the USOncology Thoracic Oncology Committee, Chair of the USOncology Research Executive Committee, and member of the USOncology National Policy Board Executive Committee. Dr. Spira is a faculty member at Johns Hopkins School of Medicine, and serves as Assistant Professor of Oncology. Throughout his career, Dr. Spira has been recognized as a Top Doctor in Northern Virginia Magazine and Washingtonian magazine for multiple years. In 2014, he received the prestigious “Castle Connolly America’s Top Doctor” award. In his spare time, Dr. Spira enjoys spending time with his family, coaching children’s sports, cycling, and cheering on his favorite New York sports teams.
[post_title] => Alex Spira, M.D., PhD, F.A.C.P. [post_excerpt] => [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => alex-spira-m-d-phd-f-a-c-p [to_ping] => [pinged] => [post_modified] => 2018-09-25 19:37:51 [post_modified_gmt] => 2018-09-25 19:37:51 [post_content_filtered] => [post_parent] => 0 [guid] => http://vacs.wpengine.com/?post_type=physician&p=547 [menu_order] => 0 [post_type] => physician [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [page_builder] => 1 ) )